T-DXd Could Be New Standard of Care for Breast Cancer Subset
Trastuzumab deruxtecan had an ORR rate of nearly 61% for patients with advanced HER2-positive breast cancer.
Related Articles
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21…
Test Predicts Neoadjuvant Treatment Response in TNBC
The DetermalO identified patients with early-stage triple-negative breast cancer who would benefit from presurgical atezolizumab plus carboplatin and nab-paclitaxel.
MR-Linac Reduced Radiation to Healthy Brain Tissue in Glioma
Weekly MR-Linac adaptive radiotherapy limited exposure to normal brain tissue in patients with high-grade glioma.
Namodenoson Gets FDA Orphan Drug Designation for Pancreatic Cancer
The FDA granted namodenoson an orphan drug designation for patients who have pancreatic cancer.
SCLC Staging Determines Treatment, Adverse Events
The staging of small cell lung cancer significantly impacts treatment plans and potential side effects.
Hematology
NT-17, a long-acting IL-7 agent, enhances CAR T-cell factors associated with efficacy in patients with relapsed/refractory DLBCL when administered 21 days post-CAR T infusion. P-BCMA-ALLO1…
AbbVie Submits BLA to Telisotuzumab Vedotin for NSCLC
A supplemental biologics license application was submitted for telisotuzumab vedotin for the treatment of metastatic EGFR wild-type nonsquamous non–small cell lung cancer.
NT-I7 Enhances CAR T-Cell Efficacy in DLBCL
NT-17, a long-acting IL-7 agent, enhances CAR T-cell factors associated with efficacy in patients with relapsed/refractory DLBCL when administered 21 days post-CAR T infusion.
AbbVie Submits BLA to Telisotuzumab Vedotin for NSCLC
A supplemental biologics license application was submitted for telisotuzumab vedotin for the treatment of metastatic EGFR wild-type nonsquamous non–small cell lung cancer.
Oncology Nurses Are the ‘Frontlines to Nutritional Deficiencies’
When it comes to cancer-related malnutrition, nurses should look out for more signs than just weight loss.